101 related articles for article (PubMed ID: 1471076)
1. DDAVP releases tPA in correlation with a fall in platelet serotonin in uraemic patients.
Malyszko J; Malyszko JS; Azzadin A; Mysliwiec M; Buczko W
Thromb Res; 1992 Nov; 68(3):303-8. PubMed ID: 1471076
[No Abstract] [Full Text] [Related]
2. A partial role of serotonin in normalization of the bleeding time by DDAVP in uraemic rats.
Pietraszek M; Azzadin A; Buczko W; Malyszko J; Mysliwiec M
Thromb Haemost; 1992 Nov; 68(5):625. PubMed ID: 1455414
[No Abstract] [Full Text] [Related]
3. [Possible role of serotonin in hemostatic the mechanism of action of desmopressin (DDAVP) in patients with uremia].
Małyszko J; Małyszko J; Pietraszek M; Azzadin A; Myśliwiec M; Buczko W
Pol Arch Med Wewn; 1993 Aug; 90(2):105-11. PubMed ID: 8247943
[TBL] [Abstract][Full Text] [Related]
4. Effect of desmopressin (DDAVP) on protein C and protein C inhibitors in uremia.
Akpolat T; Ozdemir O; Arik N; Demirkan F; Sungur C; Ozcebe O; Dündar S; Yasavul U; Turgan C; Kirazli S
Nephron; 1993; 64(2):232-4. PubMed ID: 8321356
[TBL] [Abstract][Full Text] [Related]
5. Desmopressin induces decrease in platelet serotonin content in uremia.
Małyszko J; Pietraszek MH; Azzadin A; Buczko W; Myśliwiec M
Thromb Haemost; 1989 Jun; 61(3):537. PubMed ID: 2799766
[No Abstract] [Full Text] [Related]
6. Study on mechanisms of a haemostatic effect of 1 deamino-8-D-arginine vasopressin (desmopressin) in uraemic patients.
Malyszko J; Pietraszek M; Buczko W; Mysliwiec M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(2):319-24. PubMed ID: 1697836
[TBL] [Abstract][Full Text] [Related]
7. Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on human platelets.
Yang X; Disa J; Rao AK
Thromb Res; 1990 Sep; 59(5):809-18. PubMed ID: 2237837
[TBL] [Abstract][Full Text] [Related]
8. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium.
Escolar G; Cases A; Monteagudo J; Garrido M; Lopez J; Ordinas A; Revert L; Castillo R
J Lab Clin Med; 1989 Jul; 114(1):36-42. PubMed ID: 2738447
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolytic responses to 1-desamino-8-D-arginine-vasopressin in patients with congenital nephrogenic diabetes insipidus.
Knoers N; Brommer EJ; Willems H; van Oost BA; Monnens LA
Nephron; 1990; 54(4):322-6. PubMed ID: 2109264
[TBL] [Abstract][Full Text] [Related]
10. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
[TBL] [Abstract][Full Text] [Related]
11. Desmopressin-induced improvement in bleeding times in chronic renal failure patients correlates with platelet serotonin uptake and ATP release.
Soslau G; Schwartz AB; Putatunda B; Conroy JD; Parker J; Abel RF; Brodsky I
Am J Med Sci; 1990 Dec; 300(6):372-9. PubMed ID: 2264575
[TBL] [Abstract][Full Text] [Related]
12. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion.
Keber D; Stegnar M; Kluft C
Thromb Haemost; 1990 Feb; 63(1):72-5. PubMed ID: 2111049
[TBL] [Abstract][Full Text] [Related]
13. Norepinephrine and DDAVP induced rise in tissue plasminogen activator.
Grant PJ; Wiles PG; Davies JA; Prentice CR
Thromb Haemost; 1988 Oct; 60(2):342. PubMed ID: 3146147
[No Abstract] [Full Text] [Related]
14. [Effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on bleeding time in uremic patients].
Alarcón F; Mezzano D; Vial S; Pereira J
Rev Med Chil; 1985 Aug; 113(8):763-8. PubMed ID: 3938558
[No Abstract] [Full Text] [Related]
15. The effect of venous occlusion on the PAI and antiplasmins release from platelets.
Woods AI; Nadra CA; Lazzari MA
Thromb Res; 1989 Nov; 56(3):491-5. PubMed ID: 2515615
[No Abstract] [Full Text] [Related]
16. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
Sultan Y; Loyer F; Venot A
Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
[TBL] [Abstract][Full Text] [Related]
17. Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients.
Lee HK; Kim YJ; Jeong JU; Park JS; Chi HS; Kim SB
Nephron Clin Pract; 2010; 114(4):c248-52. PubMed ID: 20090366
[TBL] [Abstract][Full Text] [Related]
18. Normal homeostasis of fibrinolysis in nephrogenic diabetes insipidus in spite of defective V2- receptor-mediated responses of tissue plasminogen activator release.
Brommer EJ; Brink H; Derkx FH; Schalekamp MA; Stibbe J
Eur J Clin Invest; 1990 Feb; 20(1):72-8. PubMed ID: 2138555
[TBL] [Abstract][Full Text] [Related]
19. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
[TBL] [Abstract][Full Text] [Related]
20. The release of factor VIII and tissue plasminogen activator can not be blocked by specific antagonists to vasopressin.
Vilhardt H; Barth T
J Recept Res; 1991; 11(1-4):239-45. PubMed ID: 1909360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
